<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="34f9bf77-6d88-5782-e063-6294a90a6c54"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use TRYNGOLZA safely and effectively. See full prescribing information for TRYNGOLZA.
 <br/>
      <br/>
TRYNGOLZA (olezarsen) injection, for subcutaneous use
 <br/>
Initial U.S. Approval: 2024
</title>
   <effectiveTime value="20250131"/>
   <setId root="0f51aa8e-8475-8cf9-e063-6394a90a6848"/>
   <versionNumber value="6"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="011829916"/>
            <name>Ionis Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="34f9fe22-759e-61b6-e063-6394a90a622c"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250131"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="71860-101" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>TRYNGOLZA</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>olezarsen sodium</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="22ADO53M6F" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3980JIH2SW" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, MONOBASIC, UNSPECIFIED FORM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="80"/>
                              <denominator unit="mL" value="0.8"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="NSY2BY6PSB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OLEZARSEN SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="S3RS2SA30L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>OLEZARSEN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="0.8" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43203" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE, GLASS"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="71860-101-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20241219"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA218614" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20241219"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="34f9bf77-6d89-5782-e063-6294a90a6c54"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>TRYNGOLZA is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).</paragraph>
               </text>
               <effectiveTime value="20241223"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>TRYNGOLZA is an
 
    <content styleCode="italics">APOC-III</content>-directed antisense oligonucleotide (ASO) indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).Â (
 
    <linkHtml href="#S1">1</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="34f9bf77-6d8a-5782-e063-6294a90a6c54"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>The recommended dosage of TRYNGOLZA is 80 mg administeredÂ subcutaneously once monthly. (
  
     <linkHtml href="#S2.1">2.1</linkHtml>)
 
    </item>
                           <item>Administer TRYNGOLZA into the abdomen or front of the thigh. The back of the upper arm can also be used as an injection site if a healthcare provider or caregiver administers the injection. (
  
     <linkHtml href="#S2.2">2.2</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="34f9bf77-6d8b-5782-e063-6294a90a6c54"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Dosage</title>
                     <text>
                        <paragraph>The recommended dosage of TRYNGOLZA is 80 mg administeredÂ subcutaneously once monthly
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="34f9bf77-6d8c-5782-e063-6294a90a6c54"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Administration Instructions</title>
                     <text>
                        <paragraph>Prior to initiation, train patients and/or caregivers on proper preparation and administration of TRYNGOLZA
 
  <content styleCode="italics">[see
  
   <linkHtml href="#IFU">Instructions for Use</linkHtml>]
 
  </content>.

 </paragraph>
                        <paragraph>Remove the single-dose autoinjector from the refrigerator 30 minutes prior to the injection and allow to warm to room temperature. Do not use other warming methods.</paragraph>
                        <paragraph>Inspect TRYNGOLZA visually for particulate matter prior to administration. The solution should be clear and colorless to yellow.
 
  <content styleCode="bold">Do not</content>use if cloudiness, particulate matter, or discoloration is observed prior to administration.

 </paragraph>
                        <paragraph>Maintain a low-fat diet (â¤20g fat per day) in conjunction with TRYNGOLZA.</paragraph>
                        <paragraph>Inject TRYNGOLZA subcutaneously into the abdomen or front of the thigh. The back of the upper arm can also be used as an injection site if a healthcare provider or caregiver administers the injection.</paragraph>
                        <paragraph>Administer TRYNGOLZA as soon as possible after a missed dose. Resume dosing at monthly intervals from the date of the most recently administered dose.</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="34f9bf77-6d8d-5782-e063-6294a90a6c54"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Injection: 80 mg/0.8 mL of olezarsen as a clear, colorless to yellow solution in a single-dose autoinjector.</paragraph>
               </text>
               <effectiveTime value="20250131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 80 mg/0.8 mL in a single-dose autoinjector. (
 
    <linkHtml href="#S3">3</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="34f9bf77-6d8e-5782-e063-6294a90a6c54"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to olezarsen or any of the excipients in TRYNGOLZA. Hypersensitivity reactions, including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills, and myalgias, requiring medical treatment have occurred
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]
 
  </content>.

 </paragraph>
               </text>
               <effectiveTime value="20241221"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>History of serious hypersensitivity reactions to olezarsen or any of the excipients in TRYNGOLZA.Â (
 
    <linkHtml href="#S4">4</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="34f9bf77-6d8f-5782-e063-6294a90a6c54"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20241221"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Hypersensitivity reactions have been reported in patients treated with olezarsen. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur.Â (
 
    <linkHtml href="#S5.1">5.1</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="34f9bf77-6d90-5782-e063-6294a90a6c54"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills, and myalgias) have been reported in patients treated with TRYNGOLZA
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]
 
  </content>. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur.

 </paragraph>
                     </text>
                     <effectiveTime value="20241221"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="34f9bf77-6d91-5782-e063-6294a90a6c54"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are discussed elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Hypersensitivity Reactions
  
   <content styleCode="italics">[</content>
                        <content styleCode="italics">see
   
    <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>
                        </content>
                        <content styleCode="italics">]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20241223"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (incidence &gt;5% of TRYNGOLZA-treated patients and &gt;3% higher frequency than placebo) were injection site reactions, decreased platelet count, and arthralgia.Â (
 
    <linkHtml href="#S6.1">6.1</linkHtml>)

   </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Ionis Pharmaceuticals Inc. at toll free number 1-833-644-6647 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="34f9bf77-6d92-5782-e063-6294a90a6c54"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of TRYNGOLZA cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The safety of TRYNGOLZA was evaluated in 66 patients with FCS enrolled in Trial 1 (NCT #04568434)
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]
 
  </content>. In this trial, 43 patients received at least one dose of TRYNGOLZA, 50 mg (N=21) or 80 mg (N=22) and 23 patients received placebo. TRYNGOLZA 50 mg is not an approved dosing regimen for FCSÂ 
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>].Â 
 
  </content>Across treatment groups, the mean age was 45 years and 42% of patients were male. Eighty-five percent (85%) of patients were White, 9% were Asian and 6% were reported as other races; 11% identified as Hispanic or Latino ethnicity. Forty-three (43) patients were exposed to TRYNGOLZA for a median of 52 weeks; 22 patients were treated with TRYNGOLZA 80 mg every 4 weeks for a median of 52 weeks.

 </paragraph>
                        <paragraph>Adverse reactions led to discontinuation of treatment in 7% of TRYNGOLZA-treated patients and 0% of placebo-treated patients. The most common reasons for TRYNGOLZA treatment discontinuation were hypersensitivity reactions. Adverse reactions (&gt;5% of patients treated with TRYNGOLZA and at &gt;3% higher frequency than placebo) are presented in Table 1.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 1. Adverse Reactions That Occurred in &gt;5% of Patients Treated with TRYNGOLZA and at &gt;3% Higher Frequency than Placebo (Trial 1)</content>
                        </paragraph>
                        <table ID="table1" width="85%">
                           <col width="36%" align="left" valign="middle"/>
                           <col width="32%" align="center" valign="middle"/>
                           <col width="32%" align="center" valign="middle"/>
                           <tbody>
                              <tr styleCode="First Last">
                                 <td align="left" styleCode="Lrule Rrule" valign="bottom">
                                    <content styleCode="bold">Adverse Reaction
     
      <footnote ID="Lb4ddc8a1-2e22-4b76-a732-152ef79b45f4">Grouped terms composed of several similar terms</footnote>
                                    </content>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Total 
       <br/>  TRYNGOLZAÂ (N = 43)
      </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="bottom">
                                    <content styleCode="bold">Placebo 
      <br/>  (N = 23)
     </content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule">Injection site reactions</td>
                                 <td align="center" styleCode="Rrule">8 (19%)</td>
                                 <td align="center" styleCode="Rrule">2 (9%)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule">Decreased platelet count</td>
                                 <td align="center" styleCode="Rrule">5 (12%)</td>
                                 <td align="center" styleCode="Rrule">1 (4%)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule Rrule">Arthralgia</td>
                                 <td align="center" styleCode="Rrule">4 (9%)</td>
                                 <td align="center" styleCode="Rrule">0</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250131"/>
                     <component>
                        <section>
                           <id root="34f9bf77-6d93-5782-e063-6294a90a6c54"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Laboratory Tests</content>
                                 <br/>
                                 <content styleCode="italics">Decrease in Platelet Count:</content>TRYNGOLZA can cause reductions in platelet count. In Trial 1, the mean platelet count in the TRYNGOLZA 80 mg group was 188,000 mm
 
  <sup>3</sup>at baseline, and the mean percent change in platelet count was -10% at Week 53. In comparison, the mean platelet count in the placebo group was 215,000/mm
 
  <sup>3</sup>at baseline, and the mean percent change in platelet count was 22% at Week 53. No TRYNGOLZA-treated patient with FCS had a platelet count &lt;50,000/mm
 
  <sup>3</sup>. There were no major bleeding events associated with a low platelet count. Overall, the proportion of patients experiencing a bleeding adverse event was similar across the TRYNGOLZA and placebo treatment groups.

 </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Increase in Glucose:</content>Small increases in average values in fasting glucose (â¤17 mg/dL) and HbA1c (&lt;0.2 percentage points) were observed over time with TRYNGOLZA treatment in the FCS population in Trial 1. The incidence of hyperglycemia (defined as adverse events, new antidiabetic medication, or laboratory values) was higher in olezarsen-treated patients without a medical history of diabetes at baseline (52%) compared to placebo-treated patients (35%).

 </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Increase in Liver Enzymes:</content>Increases from baseline in liver enzymes within the normal range were observed with olezarsen treatment in the FCS population. These increases occurred within the first 3 months of treatment and stabilized. Liver enzymes returned towards baseline with discontinuation of olezarsen.

 </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Increase in LDL-cholesterol:</content>Increases in low-density lipoprotein cholesterol (LDL-C) and total apolipoprotein B (apoB) were observed in the FCS population treated with TRYNGOLZA compared to those treated with placebo
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]
 
  </content>. Despite increases in LDL-C, the maximum LDL-C value remained low for most patients (i.e., &lt;70 mg/dL for 74% of patients treated with TRYNGOLZA).

 </paragraph>
                           </text>
                           <effectiveTime value="20241223"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="34f9bf77-6d94-5782-e063-6294a90a6c54"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20241221"/>
               <component>
                  <section ID="S8.1">
                     <id root="34f9bf77-6d95-5782-e063-6294a90a6c54"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20241221"/>
                     <component>
                        <section>
                           <id root="34f9bf77-6d96-5782-e063-6294a90a6c54"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no available data on TRYNGOLZA use in pregnant women to inform drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Patients with FCS are at risk for pancreatitis during pregnancy because of defects in lipid metabolism and increased triglyceride levels
 
  <content styleCode="italics">(see
  
   <linkHtml href="#L80e11cd5-f7b0-4b9f-9cb7-701d70d0fce4">Clinical Considerations</linkHtml>)
 
  </content>.

 </paragraph>
                              <paragraph>In animal reproduction studies conducted with the unconjugated antisense oligonucleotide (lacking GalNAc) in rabbits and mice, no adverse effects on development or pregnancy were observed at doses 21 times or 20 times, respectively, the maximum recommended clinical dose.</paragraph>
                              <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20% respectively.</paragraph>
                           </text>
                           <effectiveTime value="20241221"/>
                        </section>
                     </component>
                     <component>
                        <section ID="L80e11cd5-f7b0-4b9f-9cb7-701d70d0fce4">
                           <id root="34f9bf77-6d97-5782-e063-6294a90a6c54"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241221"/>
                           <component>
                              <section ID="Lc188fdcb-87cb-4b1c-bc6c-8ad53bdea952">
                                 <id root="34f9bf77-6d98-5782-e063-6294a90a6c54"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Disease-Associated Maternal and/or Embryo-Fetal Risk</content>
                                       <br/>  During pregnancy, triglyceride levels increase during the third trimester of pregnancy. In patients with underlying defects in lipid metabolism, such as FCS, severe gestational hypertriglyceridemia may occur, increasing the risk of acute pancreatitis during pregnancy.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20241221"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="34f9bf77-6d99-5782-e063-6294a90a6c54"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241220"/>
                           <component>
                              <section>
                                 <id root="34f9bf77-6d9a-5782-e063-6294a90a6c54"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Olezarsen was not evaluated for potential effects on embryofetal development (EFD). However, effects of the administration of the unconjugated antisense oligonucleotide (ASO), which shares the same nucleotide sequence but lacks the N-acetyl galactosamine [GalNAc] moiety
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S11">Description (11)</linkHtml>]
 
  </content>, were evaluated.

 </paragraph>
                                    <paragraph>In a combined fertility and embryo-fetal development study in mice, the unconjugated ASO was administered to male and female mice by subcutaneous injection at doses of 10.5, 35, and 87.5 mg/kg/week prior to mating and through to the completion of organogenesis (gestation day 15). No adverse developmental outcomes occurred at doses up to 87.5 mg/kg/week (approximately 21-times the monthly maximum recommended human dose (MRHD) based on a body surface area (BSA) comparison of the unconjugated ASO).</paragraph>
                                    <paragraph>In an embryo-fetal development study in pregnant rabbits, the unconjugated ASO was administered by subcutaneous injection at doses of 10.5, 21, and 52.5 mg/kg/week during the period of organogenesis (gestation days 6 to 18). No adverse developmental effects were observed at doses up to 21 mg/kg/week (approximately 20-times the monthly MRHD based on a BSA comparison of the unconjugated ASO).</paragraph>
                                    <paragraph>In a pre-/postnatal toxicity study in mice, the unconjugated ASO was administered at 10.5, 35, or 87.5 mg/kg/week during the period of organogenesis and continuing until weaning (gestation day 6 through lactation day 21). Offspring body weights at 87.5 mg/kg/week (21-times the monthly MRHD based on BSA) were lower throughout their lives and were associated with slight delays in the attainment of morphological and developmental landmarks. No adverse effects on offspring were observed at 35 mg/kg/week (approximately 9-times the monthly MRHD based on a BSA comparison of the unconjugated ASO).</paragraph>
                                 </text>
                                 <effectiveTime value="20241220"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="34f9bf77-6d9b-5782-e063-6294a90a6c54"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20241220"/>
                     <component>
                        <section>
                           <id root="34f9bf77-6d9c-5782-e063-6294a90a6c54"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no data on the presence of olezarsen in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. However, the unconjugated antisense ASO, which shares the same nucleotide sequence but lacks GalNAc, was present in the milk of lactating mice at low levels. When a drug is present in animal milk, it is likely that the drug will be present in human milk. Oligonucleotide-based products typically have poor oral bioavailability; therefore, it is considered unlikely that low levels present in milk will lead to clinically relevant levels in breastfed infants. The developmental and health benefits of breastfeeding should be considered along with the motherâs clinical need for TRYNGOLZA and any potential adverse effects on the breast-fed infant from TRYNGOLZA or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20241220"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="34f9bf77-6d9d-5782-e063-6294a90a6c54"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness of TRYNGOLZA in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20240404"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="34f9bf77-6d9e-5782-e063-6294a90a6c54"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>No dose adjustment is recommended in patients aged 65 years and older
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]
 
  </content>. In clinical studies, 111 (38%) patients treated with TRYNGOLZA were â¥65 years of age. No overall differences in safety or effectiveness of TRYNGOLZA have been observed between patients 65 years of age and older and younger adult patients.

 </paragraph>
                     </text>
                     <effectiveTime value="20241221"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="34f9bf77-6d9f-5782-e063-6294a90a6c54"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>No dose adjustment is necessary in patients with mild to moderate renal impairment (estimated glomerular filtration rate [eGFR] â¥30 to &lt;90 mL/min)
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]
 
  </content>. TRYNGOLZA has not been studied in patients with severe renal impairment or end-stage renal disease.

 </paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="34f9bf77-6da0-5782-e063-6294a90a6c54"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph>No dose adjustment is recommended in patients with mild hepatic impairment
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]
 
  </content>.Â TRYNGOLZA has not been studied in patients with moderate or severe hepatic impairment.

 </paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="34f9bf77-6da1-5782-e063-6294a90a6c54"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Olezarsen is an ASO directed inhibitor of Apolipoprotein C-III (apoC-III) mRNA, conjugated to a ligand containing three
 
  <content styleCode="italics">N</content>-acetyl galactosamine (GalNAc) residues to enable delivery of the ASO to hepatocytes.

 </paragraph>
                  <paragraph>TRYNGOLZA contains olezarsen sodium as the active ingredient. Olezarsen sodium is a white to yellow solid and it is freely soluble in water and in phosphate buffer. The molecular formula of olezarsen sodium is C
 
  <sub>296</sub>H
 
  <sub>419</sub>N
 
  <sub>71</sub>O
 
  <sub>154</sub>P
 
  <sub>20</sub>S
 
  <sub>19</sub>Na
 
  <sub>20</sub>and the molecular weight is 9124.48 daltons. The chemical name of olezarsen sodium is DNA, d(P-thio) ([2'-
 
  <content styleCode="italics">O</content>-(2-methoxyethyl)] rA-[2'-
 
  <content styleCode="italics">O</content>-(2-methoxyethyl)] rG-[2'-
 
  <content styleCode="italics">O</content>-(2-methoxyethyl)] m5rC-[2'-
 
  <content styleCode="italics">O</content>-(2-methoxyethyl)] m5rU-[2'-
 
  <content styleCode="italics">O</content>-(2-methoxyethyl)] m5rU-m5C-T-T-G-T-m5C-m5C-A-G-m5C-[2'-
 
  <content styleCode="italics">O</content>-(2-methoxyethyl)] m5rU-[2'-
 
  <content styleCode="italics">O</content>-(2-methoxyethyl)] m5rU-[2'-
 
  <content styleCode="italics">O</content>-(2-methoxyethyl)] m5rU-[2'-
 
  <content styleCode="italics">O</content>-(2-methoxyethyl)] rA-[2'-
 
  <content styleCode="italics">O</content>-(2-methoxyethyl)]m5rU), 5'-[26-[[2-(acetylamino)-2-deoxy-Î²-D-galactopyranosyl]oxy]-14,14-bis[[3-[[6-[[2-(acetylamino)-2-deoxy-Î²-D-galactopyranosyl]oxy]hexyl]amino]-3-oxopropoxy]methyl]-8,12,19-trioxo-16-oxa-7,13,20-triazahexacos-1-yl hydrogen phosphate], sodium salt (1:20).

 </paragraph>
                  <paragraph>The structure of olezarsen sodium is presented below:Â </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L1c59a487-5049-4d56-b76b-613e72d2219c"/>
                  </paragraph>
                  <paragraph>TRYNGOLZA is a sterile, preservative-free solution for subcutaneous injection. Each single-dose autoinjector contains 80 mg olezarsen (equivalent to 84 mg of olezarsen sodium) in 0.8 mL of solution. The solution also contains the following inactive ingredients: disodium hydrogen phosphate, sodium chloride, sodium dihydrogen phosphate to maintain pH and provide tonicity, and water for injection. The solution may include hydrochloric acid and/or sodium hydroxide for pH adjustment between 6.9 to 7.9. Each dose of TRYNGOLZA injection contains 6 mg of phosphorous and 5 mg of sodium.</paragraph>
               </text>
               <effectiveTime value="20241223"/>
               <component>
                  <observationMedia ID="L1c59a487-5049-4d56-b76b-613e72d2219c">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="tryngolza-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="34f9bf77-6da2-5782-e063-6294a90a6c54"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250131"/>
               <component>
                  <section ID="S12.1">
                     <id root="34f9bf77-6da3-5782-e063-6294a90a6c54"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Olezarsen is an ASO-GalNAc
 
  <sub>3</sub>conjugate that binds to apoC-III mRNA leading to mRNA degradation and resulting in a reduction of serum apoC-III protein. Reduction of apoC-III protein leads to increased clearance of plasma TG and VLDL.

 </paragraph>
                     </text>
                     <effectiveTime value="20250324"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="34f9bf77-6da4-5782-e063-6294a90a6c54"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Fasting apoC-III</content>
                           <br/>  Olezarsen decreased fasting apoC-III following administration of TRYNGOLZA 80 mg dosage every 4 weeks to patients with FCS
 
  <content styleCode="italics">[See
  
   <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]
 
  </content>. The placebo-corrected percent change in fasting apoC-III from baseline was -57% at 1 month, -69% at 3 months, -72% at 6 months, and -80% at 12 months.

 </paragraph>
                     </text>
                     <effectiveTime value="20241222"/>
                     <component>
                        <section>
                           <id root="34f9bf77-6da5-5782-e063-6294a90a6c54"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cardiac Electrophysiology</content>
                              </paragraph>
                              <paragraph>At a dose 1.5-times the maximum approved recommended dosage, TRYNGOLZA does not prolong the QT interval to any clinically relevant extent.</paragraph>
                           </text>
                           <effectiveTime value="20241222"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="34f9bf77-6da6-5782-e063-6294a90a6c54"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Olezarsen steady state mean (SD) maximum concentrations (C
 
  <sub>max</sub>) is 883 (662) ng/mL and area under the curve (AUC
 
  <sub>Ï</sub>) is 7440 (3880) ng*h/mL at the approved recommended dosage in patients with FCS. Olezarsen C
 
  <sub>max</sub>and AUC increase dose-proportionally following single subcutaneous doses ranging from 10 to 120 mg (i.e., 0.13- to 1.5-times the approved recommended dose) in healthy volunteers. No olezarsen accumulation occurs with repeat dosing.

 </paragraph>
                     </text>
                     <effectiveTime value="20250324"/>
                     <component>
                        <section>
                           <id root="34f9bf77-6da7-5782-e063-6294a90a6c54"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>Olezarsen time to C
 
  <sub>max</sub>(T
 
  <sub>max</sub>) is approximately 2 hours following subcutaneous administration.

 </paragraph>
                           </text>
                           <effectiveTime value="20241222"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="34f9bf77-6da8-5782-e063-6294a90a6c54"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>The population estimates for the apparent central volume of distribution is 91.9 L and the apparent peripheral volume of distribution is 2960 L for olezarsen. Olezarsen is greater than 99% bound to plasma proteins,
 
  <content styleCode="italics">in vitro</content>.

 </paragraph>
                              <paragraph>Olezarsen distributes primarily to the liver and kidney after subcutaneous dosing.</paragraph>
                           </text>
                           <effectiveTime value="20250324"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="34f9bf77-6da9-5782-e063-6294a90a6c54"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>Olezarsen terminal elimination half-life is approximately 4 weeks.</paragraph>
                           </text>
                           <effectiveTime value="20250324"/>
                           <component>
                              <section>
                                 <id root="34f9bf77-6daa-5782-e063-6294a90a6c54"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">Metabolism</content>
                                    </paragraph>
                                    <paragraph>Olezarsen is metabolized by endo- and exonucleases to short oligonucleotide fragments of varying sizes within the liver.</paragraph>
                                 </text>
                                 <effectiveTime value="20250324"/>
                                 <component>
                                    <section>
                                       <id root="34f9bf77-6dab-5782-e063-6294a90a6c54"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Excretion</content>
                                          </paragraph>
                                          <paragraph>Less than 1% of olezarsen administered dose is eliminated unchanged in urine within 24 hours.</paragraph>
                                       </text>
                                       <effectiveTime value="20250324"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="34f9bf77-6dac-5782-e063-6294a90a6c54"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                              <paragraph>No clinically significant differences in the pharmacokinetics of olezarsen were observed based on age (&lt; 65 to â¥ 75 years), body weight, sex, race (White, Black or African American, Asian, Japanese, American Indian or Alaska Native, Native Hawaiian or Pacific Islander), mild-to-moderate renal impairment (eGFR â¥30 to &lt;90 mL/min) [CKD-EPI], or mild hepatic impairment (total bilirubin â¤ ULN and AST &gt; ULN, or total bilirubin &gt;1 to 1.5 x ULN and any AST, National Cancer Institute Organ Dysfunction Working Group criteria). The effect of severe renal impairment (eGFR &lt; 30 mL/min), end-stage renal disease, moderate or severe hepatic impairment (total bilirubin &gt; 1.5 x ULN with any AST) on olezarsen pharmacokinetics is unknown.</paragraph>
                           </text>
                           <effectiveTime value="20250131"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="34f9bf77-6dad-5782-e063-6294a90a6c54"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">In Vitro Studies</content>
                                 <br/>
                                 <content styleCode="italics">
                                    <content styleCode="underline">CYP450 Enzymes:</content>
                                 </content>Olezarsen is not an inhibitor or inducer of CYP450 enzymes.

 </paragraph>
                              <paragraph>
                                 <content styleCode="underline">
                                    <content styleCode="italics">Transporter Systems:</content>
                                 </content>Â Olezarsen is not a substrate or inhibitor of OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, MATE1, MATE2-K, BCRP, P-gp, and BSEP.

 </paragraph>
                              <paragraph>
                                 <content styleCode="underline">
                                    <content styleCode="italics">Protein Binding:</content>
                                 </content>Olezarsen does not displace warfarin and ibuprofen from plasma protein binding sites.

 </paragraph>
                           </text>
                           <effectiveTime value="20241222"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.6">
                     <id root="34f9bf77-6dae-5782-e063-6294a90a6c54"/>
                     <code code="88830-5" codeSystem="2.16.840.1.113883.6.1" displayName="IMMUNOGENICITY"/>
                     <title>12.6 Immunogenicity</title>
                     <text>
                        <paragraph>The observed incidence of anti-drug antibodies (ADAs) is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of ADAs in the study described below with the incidence of anti-drug antibodies in other studies, including those of olezarsen.</paragraph>
                        <paragraph>In Trial 1, with duration of treatment up to 53 weeks, 18 out of 43 (42%) patients treated with TRYNGOLZA developed treatment-emergent ADAs. The presence of ADAs did not affect olezarsen plasma C
 
  <sub>max</sub>, but increased C
 
  <sub>trough</sub>. Although ADA development was not found to affect the pharmacodynamics, safety, or efficacy of TRYNGOLZA in these patients, the available data are limited to make definitive conclusions.

 </paragraph>
                     </text>
                     <effectiveTime value="20241221"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="34f9bf77-6daf-5782-e063-6294a90a6c54"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20241221"/>
               <component>
                  <section ID="S13.1">
                     <id root="34f9bf77-6db0-5782-e063-6294a90a6c54"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20250324"/>
                     <component>
                        <section>
                           <id root="34f9bf77-6db1-5782-e063-6294a90a6c54"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>No long-term carcinogenicity studies were conducted with olezarsen in animals. However, the unconjugated antisense oligonucleotide (ASO) lacking GalNAc was administered weekly in mice and rats at subcutaneous doses of 0, 6, 25 and 40 mg/kg/week (along with a mouse-specific surrogate ASO at 25 mg/kg/week) and 0, 0.2, 1 and 5 mg/kg/week, respectively, for 2 years. In male mice, there were statistically significant increases in the incidences of hepatocellular adenomas and carcinomas at â¥25 mg/kg/week and hemangiomas and hemangiosarcomas at all doses. In female mice, there were statistically significant increases in the incidences of histiocytic sarcomas at all doses (including the mouse-specific surrogate) and pituitary gland adenomas at 25 mg/kg/week. In rats, the incidence of malignant fibrous histiocytoma at the injection site was increased in both sexes at doses â¥1 mg/kg/week. These tumors are considered a response to chronic tissue irritation and inflammation caused by repeated subcutaneous injection. The clinical significance of these findings is uncertain.</paragraph>
                           </text>
                           <effectiveTime value="20250131"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="34f9bf77-6db2-5782-e063-6294a90a6c54"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Olezarsen was negative for genotoxicity in vitro (bacterial reverse mutation assay and chromosome aberration assay in Chinese hamster lung cells) and in vivo (mouse bone marrow micronucleus assay).</paragraph>
                           </text>
                           <effectiveTime value="20241221"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="34f9bf77-6db3-5782-e063-6294a90a6c54"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>Olezarsen was administered at doses of 0, 5, 10, or 20 mg/kg given every other week to male and female mice prior to mating, followed by every other day dosing after mating and until gestation day 6 in females. There was no effect on fertility in mice administered olezarsen at doses up to 20 mg/kg (approximately 2-times the monthly maximum recommended human dose based on body surface area).</paragraph>
                           </text>
                           <effectiveTime value="20241220"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="34f9bf77-6db4-5782-e063-6294a90a6c54"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>-The efficacy of TRYNGOLZA was demonstrated in a randomized, placebo-controlled, double-blind clinical trial in adult patients with genetically identified FCS and fasting triglyceride (TG) levels â¥880 mg/dL (Trial 1;Â 
 
  <linkHtml href="https://clinicaltrials.gov/ct2/show/record/NCT04568434">NCT04568434</linkHtml>). After a â¥4-week run-in period where patients continued to follow a low-fat diet with â¤20 grams fat per day, patients were randomly assigned to receive doses every 4 weeks of TRYNGOLZA 80 mg (n=22) or matching volume of placebo (n=23) via subcutaneous injection over a 53-week treatment period.

 </paragraph>
                  <paragraph>Patient demographic and baseline characteristics were generally similar across the treatment groups
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6">Adverse Reactions (6.1)</linkHtml>]
 
  </content>.Â The proportion of patients with diabetes at enrollment was 32% in theÂ TRYNGOLZA 80 mg group compared with 26% in the placebo group. Patients in the TRYNGOLZA 80 mg and placebo groups were treated with statins (27%), omega-3 fatty acids (42%), fibrates (49%), or other lipid lowering therapies (13%) at study entry. Seventy-one percent (71%) of patients in the TRYNGOLZA 80 mg and placebo groups combined had a history of documented acute pancreatitis in the prior 10 years. Mean (SD) and median fasting TG levels at baseline were 2,604 (1,364) mg/dL and 2,303 mg/dL, respectively (range of 334 to 6,898 mg/dL).

 </paragraph>
                  <paragraph>The primary endpoint was percent change in fasting triglycerides from baseline to Month 6 (average of Weeks 23, 25, and 27) compared to placebo. The difference between TRYNGOLZA 80 mg group and the placebo group in percent change in fasting triglycerides from baseline to Month 6 was -42.5% (95% CI: -74.1%, -10.9%; p=0.0084). For additional results see Table 2.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Table 2. Mean Baseline (BL) and Mean Percent (%) Changes from Baseline in Lipid/ Lipoprotein Parameters in Patients with FCS at Month 6 in Trial 1</content>
                  </paragraph>
                  <table ID="table2" width="90%">
                     <col width="15%"/>
                     <col width="15%"/>
                     <col width="15%"/>
                     <col width="15%"/>
                     <col width="15%"/>
                     <col width="25%"/>
                     <tbody>
                        <tr styleCode="First Last">
                           <td colspan="6" align="left">Abbreviations: apoB = apolipoprotein B; non-HDL-C = non high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol. 
     <br/>  Note: Analyses results were based on an analysis of covariance model with treatment, the two randomization stratification factors, prior history of pancreatitis within 10 years prior to Screening (yes vs. no), previous treatment with the unconjugated ASO (yes vs. no) as the fixed effects and log-transformed Baseline value as a covariate. Missing data was imputed using placebo washout imputation. The 95% CIs of treatment differences were calculated using a robust variance estimator. For triglycerides and non-HDL, a test of residual normality did not indicate significant departure from normal distribution.
    </td>
                        </tr>
                     </tbody>
                     <tbody>
                        <tr align="center" valign="middle">
                           <td rowspan="2" align="center" styleCode="First Last Lrule">
                              <content styleCode="bold">Parameter 
      <br/>  (mg/dL)
     </content>
                           </td>
                           <td colspan="2" align="center" styleCode="First Lrule">
                              <content styleCode="bold">TRYNGOLZA 
      <br/>  80 mg 
      <br/>  N = 22
     </content>
                              <paragraph/>
                           </td>
                           <td colspan="2" align="center" styleCode="First Lrule">
                              <content styleCode="bold">Placebo 
      <br/>  N = 23
     </content>
                              <paragraph/>
                           </td>
                           <td align="center" styleCode="First Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">TRYNGOLZA 
       <br/>  80 mg 
       <br/>  vs. Placebo
      </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr align="center" valign="middle">
                           <td align="center" styleCode="Lrule Toprule">
                              <content styleCode="bold">BL</content>
                           </td>
                           <td align="center" styleCode="Lrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">% changeÂ </content>
                                 <content styleCode="bold">Month 6</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Lrule Toprule">
                              <content styleCode="bold">BL</content>
                           </td>
                           <td align="center" styleCode="Lrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">% changeÂ Month 6</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Lrule Rrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">Treatment DifferenceÂ </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">% changeÂ (95% CI)Â atÂ Month 6</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr align="center" valign="middle">
                           <td align="center" styleCode="Lrule Rrule Toprule">
                              <content styleCode="bold">Â Triglycerides</content>
                           </td>
                           <td align="center" styleCode="Lrule Rrule Toprule">2613.1</td>
                           <td align="center" styleCode="Lrule Rrule Toprule">-30</td>
                           <td align="center" styleCode="Lrule Rrule Toprule">2595.7</td>
                           <td align="center" styleCode="Lrule Rrule Toprule">+12Â </td>
                           <td align="center" styleCode="Lrule Rrule Toprule">-42.5
    
     <footnote ID="Lf3730fc2-14dd-4b44-807c-3ec6e7912cda">Reached statistical significance (p value &lt; 0.05).</footnote>
                              <br/>  (-74.1, -10.9)
   
    </td>
                        </tr>
                        <tr align="center" valign="middle">
                           <td styleCode="Lrule Rrule Toprule">
                              <content styleCode="bold">Â Non-HDL-C</content>
                           </td>
                           <td styleCode="Lrule Rrule Toprule">262.9</td>
                           <td styleCode="Lrule Rrule Toprule">-18</td>
                           <td styleCode="Lrule Rrule Toprule">271.3</td>
                           <td styleCode="Lrule Rrule Toprule">+5.7Â </td>
                           <td styleCode="Lrule Rrule Toprule">-23.4 
     <br/>  (-45.3, -1.5)
    </td>
                        </tr>
                        <tr align="center" valign="middle">
                           <td styleCode="Lrule Rrule Toprule">
                              <content styleCode="bold">Â LDL-C</content>
                           </td>
                           <td styleCode="Lrule Rrule Toprule">22.8</td>
                           <td styleCode="Lrule Rrule Toprule">+64</td>
                           <td styleCode="Lrule Rrule Toprule">16.7</td>
                           <td styleCode="Lrule Rrule Toprule">+9Â </td>
                           <td styleCode="Lrule Rrule Toprule">+55.0
    
     <footnote ID="L18adc658-ab66-4286-90a7-3cd0d9b4ccff">Mean LDL-C levels increased but remained within normal range (i.e., &lt;70 mg/dL for 74% of patients treated with TRYNGOLZA).</footnote>
                              <br/>  (0.7, 109.4)
   
    </td>
                        </tr>
                        <tr align="center" valign="middle">
                           <td styleCode="Lrule Rrule Toprule">
                              <content styleCode="bold">Â Total ApoB</content>
                           </td>
                           <td styleCode="Lrule Rrule Toprule">58.4</td>
                           <td styleCode="Lrule Rrule Toprule">+20</td>
                           <td styleCode="Lrule Rrule Toprule">59.7</td>
                           <td styleCode="Lrule Rrule Toprule">+9</td>
                           <td styleCode="Lrule Rrule Toprule">+11.7 
     <br/>  (-12.6, 35.9)
    </td>
                        </tr>
                        <tr align="center" valign="middle">
                           <td styleCode="Lrule Rrule Toprule">
                              <content styleCode="bold">Â ApoB-48</content>
                           </td>
                           <td styleCode="Lrule Rrule Toprule">11.6</td>
                           <td styleCode="Lrule Rrule Toprule">-51</td>
                           <td styleCode="Lrule Rrule Toprule">14.2</td>
                           <td styleCode="Lrule Rrule Toprule">+25</td>
                           <td styleCode="Lrule Rrule Toprule">-75.9 
     <br/>  (-149.8, -2.0)
    </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Median percent change from baseline (Figure 1) and median absolute TG values (Figure 2) over time demonstrated a consistent lowering effect during the 12-month treatment period.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 1. Percent Change in Fasting Triglyceride (mg/dL) Over Time</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="Lcc90abda-aed8-4c71-b1b2-df5f2e741e21"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 2. Fasting Triglyceride (mg/dL) Over Time</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="Lcbe6b3db-268d-489c-9a03-5bd692096195"/>
                     </content>
                  </paragraph>
                  <paragraph>Over the 12-month treatment period, the numerical incidence of acute pancreatitis in patients treated with TRYNGOLZA 80 mg was lower compared with placebo [1 (5%) patient in the TRYNGOLZA 80 mg group compared with 7 (30%) patients in the placebo group]; all of these patients had a prior history of pancreatitis within 10 years prior to screening.</paragraph>
               </text>
               <effectiveTime value="20250131"/>
               <component>
                  <observationMedia ID="Lcc90abda-aed8-4c71-b1b2-df5f2e741e21">
                     <text>Figure 1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="tryngolza-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Lcbe6b3db-268d-489c-9a03-5bd692096195">
                     <text>Figure 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="tryngolza-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="34f9bf77-6db5-5782-e063-6294a90a6c54"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20241220"/>
               <component>
                  <section ID="S16.1">
                     <id root="34f9bf77-6db6-5782-e063-6294a90a6c54"/>
                     <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
                     <title>16.1 How Supplied</title>
                     <text>
                        <paragraph>TRYNGOLZA injection is a sterile, preservative-free, clear, colorless to yellow solution supplied in a single-dose autoinjector. Each autoinjector of TRYNGOLZA is filled to deliver 0.8 mL of solution containing 80 mg of olezarsen.</paragraph>
                        <paragraph>TRYNGOLZA is available in cartons containing one 80 mg single-dose autoinjector each (NDC 71860-101-01).</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
               <component>
                  <section ID="S16.2">
                     <id root="34f9bf77-6db7-5782-e063-6294a90a6c54"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>16.2 Storage and Handling</title>
                     <text>
                        <paragraph>Store the TRYNGOLZA autoinjector in the refrigerator between 2Â°C and 8Â°C (36Â°F and 46Â°F) in the original carton.</paragraph>
                        <paragraph>Once taken out of the refrigerator, the TRYNGOLZA autoinjector can be stored at room temperature between 15Â°C and 30Â°C (59Â°F and 86Â°F) in the original carton for up to 6 weeks. If not used within the 6 weeks stored at room temperature, discard TRYNGOLZA.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Do not</content>freeze.
 
  <content styleCode="bold">Do not</content>expose to heat
 
  <content styleCode="bold">.</content>Protect from light.

 </paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="34f9bf77-6db8-5782-e063-6294a90a6c54"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).</paragraph>
               </text>
               <effectiveTime value="20241223"/>
               <component>
                  <section>
                     <id root="34f9bf77-6db9-5782-e063-6294a90a6c54"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hypersensitivity</content>
                        </paragraph>
                        <paragraph>Inform patients that serious hypersensitivity reactions, including bronchospasm, diffuse erythema, facial swelling, urticaria, chills, and myalgia, have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct them to stop taking TRYNGOLZA and seek medical advice promptly if such symptoms occur
 
  <content styleCode="italics">Â [see
  
   <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="34f9bf77-6dba-5782-e063-6294a90a6c54"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Adherence to Diet</content>
                        </paragraph>
                        <paragraph>Advise patients with FCS that use of lipid-regulating agents does not reduce the importance of adhering to a low-fat diet
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2">Dosage and Administration (2)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="34f9bf77-6dbb-5782-e063-6294a90a6c54"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Missed Dose</content>
                        </paragraph>
                        <paragraph>Instruct patients to take TRYNGOLZA as prescribed. If a dose is missed, instruct patients to take it as soon as they remember. Resume dosing at monthly intervals from the date of the most recently administered doseÂ 
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20241223"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="34f9bf77-6dbc-5782-e063-6294a90a6c54"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Distributed by</content>: Ionis Pharmaceuticals Inc., Carlsbad, CA 92010

 </paragraph>
                  <paragraph>TRYNGOLZA is a trademark of Ionis Pharmaceuticals Inc. All other trademarks are the property of their respective owners.</paragraph>
                  <paragraph>Â© 2024 IONIS Pharmaceuticals Inc.</paragraph>
               </text>
               <effectiveTime value="20241223"/>
            </section>
         </component>
         <component>
            <section>
               <id root="34f9bf77-6dbd-5782-e063-6294a90a6c54"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%">
                     <col width="70%" align="left" valign="top"/>
                     <col width="30%" align="right" valign="top"/>
                     <thead>
                        <tr styleCode="First Last">
                           <th colspan="2" align="center" styleCode="Lrule Rrule">PATIENT INFORMATION 
     <br/>  TRYNGOLZAÂ â¢ [trin-GOLE-zah] 
     <br/>  (olezarsen) 
     <br/>  injection, for subcutaneous use
    </th>
                        </tr>
                     </thead>
                     <tfoot>
                        <tr styleCode="First Last">
                           <td align="left">This Patient Information has been approved by the U.S. Food and Drug Administration.</td>
                           <td align="right">Approved: 12/2024</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">What is TRYNGOLZA?</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule Rrule">TRYNGOLZA is a prescription medicine used along with diet to reduce triglycerides (fat in the blood) in the treatment of adults with a condition that keeps the body from breaking down fats called familial chylomicronemia syndrome (FCS).</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" align="left" styleCode="Lrule Rrule">It is not known if TRYNGOLZA is safe and effective in children.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">Do not use TRYNGOLZA if:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>you have had a serious allergic reaction to olezarsen or any of the ingredients in TRYNGOLZA. See the end of this Patient Information for a complete list of ingredients.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">Before using TRYNGOLZA, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <br/>
                              <list listType="unordered">
                                 <item>are pregnant or plan to become pregnant. It is not known if TRYNGOLZA can harm your unborn baby. Tell your healthcare provider if you become pregnant while using TRYNGOLZA.</item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if TRYNGOLZA passes into your breast milk and if it can harm your baby. Talk to your healthcare provider about the best way to feed your baby while using TRYNGOLZA.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content>including prescription and over-the-counter medicines, vitamins, and herbal supplements.
   
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" align="left" styleCode="Lrule Rrule">Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I use TRYNGOLZA?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Read the detailed
      
       <content styleCode="bold">Instructions for Use</content>that comes with your TRYNGOLZA single-dose autoinjector.
     
      </item>
                                 <item>Your healthcare provider will show you and/or your caregiver how to inject TRYNGOLZA the first time.</item>
                                 <item>TRYNGOLZA is injected under your skin (subcutaneous use) in your stomach area (abdomen) or the front of your upper legs (thighs). Only aÂ healthcare provider or caregiver may give you an injection in the back of your upper arm.</item>
                                 <item>TRYNGOLZA should be injected 1 time each month.</item>
                                 <item>If you miss a dose, take the missed dose as soon as possible. Then inject TRYNGOLZA 1 month from the date of your last dose to get back on a monthly dosing schedule. If you have questions about your dosing schedule, ask your healthcare provider.</item>
                                 <item>Stay on your low-fat diet (less than 20 grams of fat each day) while using TRYNGOLZA.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the possible side effects of TRYNGOLZA?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Allergic reactions</content>: TRYNGOLZA can cause side effects including allergic reactions that may be serious. Allergic reactions can include redness of the skin, red itchy bumps (hives), swelling of the face, chills or trouble breathing. Stop taking TRYNGOLZA and call your healthcare provider or get emergency help right away if you have any of these symptoms.
     
      </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">The most common side effects of TRYNGOLZA include:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>Injection site reactions (such as redness or pain at the injection site)</item>
                                 <item>decreased platelet count (blood cells that help to clot blood)</item>
                                 <item>joint pain or stiffness</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule Rrule">These are not all the possible side effects of TRYNGOLZA. Tell your healthcare provider if you have any side effect that bothers you or that does not go away while taking TRYNGOLZA.Â Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I store TRYNGOLZA?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store TRYNGOLZA autoinjector in the refrigerator between 36Â°F to 46Â°F (2Â°C to 8Â°C) in the original carton.</item>
                                 <item>TRYNGOLZA can also be stored at room temperature between 59Â°F to 86Â°F (15Â°C to 30Â°C) in the original carton for up to 6 weeks.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content>let TRYNGOLZA reach temperatures above 86Â°F (30Â°C).
     
      </item>
                                 <item>
                                    <content styleCode="bold">Throw away</content>the TRYNGOLZA autoinjector if kept at room temperature
      
       <content styleCode="bold">longer than 6 weeks</content>.
     
      </item>
                                 <item>
                                    <content styleCode="bold">Do not</content>freeze.
     
      </item>
                                 <item>
                                    <content styleCode="bold">Do not</content>expose TRYNGOLZA autoinjector to heat.
     
      </item>
                                 <item>Protect from light.</item>
                                 <item>Keep the TRYNGOLZA autoinjector in the carton until ready to use.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content>store the autoinjector with the clear cap removed.
     
      </item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">Keep TRYNGOLZA and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">General information about the safe and effective use of TRYNGOLZA.</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" align="left" styleCode="Lrule Rrule">Medicines are sometimes prescribed for purposes other than those listed in a Patient Information Leaflet. Do not use TRYNGOLZA for a condition for which it was not prescribed. Do not give TRYNGOLZA to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about TRYNGOLZA that is written for health professionals.</td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the ingredients in TRYNGOLZA?</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">Active ingredient:</content>olezarsen sodium.
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">Inactive ingredients:</content>Â disodium hydrogen phosphate, sodium chloride, sodium dihydrogen phosphate to maintain pH and provide tonicity and water for injection. The solution may include hydrochloric acid and/or sodium hydroxide for pH adjustment.
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">Distributed by</content>: Ionis Pharmaceuticals Inc. Carlsbad, CA 92010
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule Rrule">TRYNGOLZA is a trademark of Ionis Pharmaceuticals Inc. All other trademarks are the property of their respective owners.</td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule Rrule">For more information, go to www.TRYNGOLZA.com or call 1-833-644-6647. If you still have questions, contact your healthcare provider.</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
               </text>
               <effectiveTime value="20241223"/>
            </section>
         </component>
         <component>
            <section ID="IFU">
               <id root="34f9bf77-6dbe-5782-e063-6294a90a6c54"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <text>
                  <table width="100%">
                     <col width="3%" align="left" valign="top"/>
                     <col width="47%" align="left" valign="top"/>
                     <col width="20%" align="center" valign="top"/>
                     <col width="30%" align="center" valign="top"/>
                     <thead>
                        <tr styleCode="First Last">
                           <th colspan="4" align="center" styleCode="Lrule Rrule">INSTRUCTIONS FOR USE 
     <br/>  TRYNGOLZA
    
     <content styleCode="bold">â¢</content>[trin-GOLE-zah] 
     <br/>  (olezarsen) 
     <br/>  injection, for subcutaneous use 
     <br/>  Single-dose autoinjector 
     <br/>  80 mg/0.8 mL
   
    </th>
                        </tr>
                     </thead>
                     <tfoot>
                        <tr styleCode="First Last">
                           <td colspan="3" align="left">This Instructions for Use has been approved by the U.S. Food and Drug Administration.</td>
                           <td align="right">Approved: 12/2024</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td colspan="4" align="left" styleCode="Lrule Rrule">This Instructions for Use contains information on how to inject
    
     <content styleCode="bold">TRYNGOLZAâ¢</content>using the autoinjector.
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Read this Instructions for Use before you start using your TRYNGOLZA autoinjector and each time you get a refill. There may be new information.</content>This information does not take the place of talking to your healthcare provider about your medical condition or treatment. Your healthcare provider should show you or your caregiver how to use the
     
      <content styleCode="bold">TRYNGOLZA</content>autoinjector the right way. If you or your caregiver have any questions, talk to your healthcare provider.
    
     </paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" align="center" styleCode="Lrule Rrule">
                              <renderMultiMedia referencedObject="MM6"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">Important information:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">TRYNGOLZA</content>is injected under the skin (subcutaneous use) only.
     
      </item>
                                 <item>Each autoinjector contains 1 single-dose and can only be used 1 time.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content>remove the clear cap until you are ready to inject
      
       <content styleCode="bold">TRYNGOLZA</content>(See
      
       <linkHtml href="#step5">Step 5</linkHtml>).
     
      </item>
                                 <item>
                                    <content styleCode="bold">Do not</content>share your autoinjector with anyone.
     
      </item>
                                 <item>
                                    <content styleCode="bold">Do not</content>use if the autoinjector appears damaged.
     
      </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Storage information:</content>
                              </paragraph>
                              <paragraph/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store the autoinjector in the refrigerator between 36Â°F to 46Â°F (2Â°C to 8Â°C) in the original carton.</item>
                                 <item>TRYNGOLZA can also be stored at room temperature between 59Â°F to 86Â°F (15Â°C to 30Â°C) in the original carton for up to 6 weeks.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content>let TRYNGOLZA reach temperatures above 86Â°F (30Â°C).
     
      </item>
                                 <item>
                                    <content styleCode="bold">Throw away</content>the TRYNGOLZA autoinjector if kept at room temperature
      
       <content styleCode="bold">longer than 6 weeks</content>.
     
      </item>
                                 <item>
                                    <content styleCode="bold">Do not</content>freeze.
     
      </item>
                                 <item>
                                    <content styleCode="bold">Do not</content>expose the autoinjector to heat.
     
      </item>
                                 <item>Protect from light.</item>
                                 <item>Keep the autoinjector in the carton until ready to use.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content>store the autoinjector with the clear cap removed.
     
      </item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">Keep TRYNGOLZA and all medicine out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">Parts of your TRYNGOLZA autoinjector</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center" styleCode="Lrule" valign="middle">
                              <content styleCode="bold">Single-dose autoinjector</content>
                           </td>
                           <td colspan="2" align="center" styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM7"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center" styleCode="Lrule" valign="middle">
                              <content styleCode="bold">Other supplies (not included)</content>
                           </td>
                           <td align="center" valign="middle">
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM8"/>
                                 <br/>  Alcohol wipe
    
     </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM9"/>
                              <br/>  Sharps container
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center" styleCode="Lrule" valign="middle"/>
                           <td align="center">
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM10"/>
                                 <br/>  Cotton ball or gauze
    
     </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM11"/>
                              <br/>  Small bandage
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" styleCode="Toprule Lrule Rrule">
                              <content styleCode="bold">Preparing to inject TRYNGOLZA</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">Step 1 Remove from the refrigerator 
      <br/>  a)
     </content>Remove the autoinjector from the refrigerator.
   
    </td>
                           <td rowspan="3" colspan="2" align="center" styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM12"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">b) Keep the autoinjector in the original carton and</content>let the autoinjector come to room temperature for 30 minutes before injecting.
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">Do not</content>try to speed up the warming process using other heat sources, such as a microwave or hot water.
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">Step 2 Check the medicine</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">a)</content>Check the expiration (EXP) date.
   
    </td>
                           <td rowspan="3" colspan="2" align="center" styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM13"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">b)</content>Check the medicine through the viewing window. The
    
     <content styleCode="bold">TRYNGOLZA</content>medicine should be clear and colorless to yellow. There should be no particles. It is normal to see air bubbles in the solution.
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">Do notÂ </content>use the autoinjector if the:
    
     <list listType="unordered" styleCode="Disc">
                                 <item>clear cap is missing or not attached.</item>
                                 <item>expiration (EXP) date has passed
      
       <content styleCode="bold">.</content>
                                 </item>
                                 <item>medicine looks cloudy, discolored, or has particles.</item>
                                 <item>autoinjector appears damaged.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">Step 3 Choose the injection site</content>
                           </td>
                           <td rowspan="4" colspan="2" align="center" styleCode="Rrule" valign="top">
                              <renderMultiMedia referencedObject="MM14"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">a)</content>Choose an injection site on the stomach or the front of the thigh.
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">b)</content>Only your healthcare provider or caregivers may choose the back of upper arm.
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">Do notÂ </content>inject:
    
     <list listType="unordered" styleCode="Disc">
                                 <item>within 2 inches (5 cm) of the belly button (navel).</item>
                                 <item>into skin that is bruised, tender, red, or hard.</item>
                                 <item>into scars or damaged skin.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">Step 4 Wash hands and clean the injection site</content>
                           </td>
                           <td rowspan="4" colspan="2" align="center" styleCode="Botrule Rrule" valign="top">
                              <renderMultiMedia referencedObject="MM15"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">a)</content>Wash your hands with soap and water.
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">b)</content>Clean the injection site with an alcohol wipe in a circular motion. Let the skin air dry.
   
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">Do not</content>touch the cleaned skin before injecting.
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">Injecting TRYNGOLZA</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">Step 5 Remove and throw away the clear cap</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">a)</content>Hold the autoinjector by the middle with the clear cap facing away from you.
   
    </td>
                           <td rowspan="4" colspan="2" align="center" styleCode="Rrule" valign="top">
                              <renderMultiMedia referencedObject="MM16"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">b)</content>Remove the clear cap by pulling it straight off.
    
     <content styleCode="bold">Do not</content>twist it off. The needle is inside the orange needle shield.
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">c)</content>Throw away the clear cap in the trash or sharps container.
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Do not</content>remove the clear cap until right before you inject.
     
      </item>
                                 <item>
                                    <content styleCode="bold">Do not</content>recap the autoinjector.
     
      </item>
                                 <item>
                                    <content styleCode="bold">Do not</content>push the orange needle shield against the hand or finger.
     
      </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">Step 6 Begin injection</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">a)</content>Hold the autoinjector in 1 hand. Place the orange needle shield at a 90-degree angle against your skin. Make sure you can see the viewing window.
   
    </td>
                           <td rowspan="5" colspan="2" align="center" styleCode="Rrule" valign="top">
                              <renderMultiMedia referencedObject="MM17"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">b)</content>Push firmly and hold the autoinjector straight against the skin. You will hear a click as the injection starts.
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">You may hear a second click. This is normal. The procedure is not finished.</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">c)</content>Hold the autoinjector against the skin for 10 seconds to make sure the full dose has been given.
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">Do not</content>move, turn, or change the angle of the autoinjector during the injection.
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">Step 7 Finish injection</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">a)</content>Check that the orange plunger rod has moved down to fill the entire viewing window.
    
     <list listType="unordered" styleCode="Disc">
                                 <item>If the orange plunger rod does not fill the viewing window, you may not have received the full dose.</item>
                                 <item>If this happens or if you have other concerns, contact your healthcare provider.</item>
                              </list>
                           </td>
                           <td rowspan="5" colspan="2" align="center" styleCode="Botrule Rrule" valign="top">
                              <renderMultiMedia referencedObject="Le86faab5-9eb3-432e-8065-e4ca7fc48470"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">b)</content>Remove the autoinjector by lifting it straight up. After removal from the skin, the orange needle shield locks into place and covers the needle.
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">c)</content>There may be a small amount of blood or liquid where you injected. This is normal.
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">If needed, press a cotton ball or gauze on the area and apply a small bandage.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">Do not</content>reuse the autoinjector.
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">Throwing away TRYNGOLZA</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule" valign="top">
                              <content styleCode="bold">Step 8 Throw away autoinjector</content>
                           </td>
                           <td rowspan="3" colspan="2" align="center" styleCode="Rrule" valign="top">
                              <renderMultiMedia referencedObject="MM19"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">a)</content>Put the used autoinjector in a sharps container right away after use.
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" styleCode="Lrule">
                              <content styleCode="bold">Do not</content>throw away the autoinjector in your household trash. 
     <br/>
                              <content styleCode="bold">Do not</content>recycle your used sharps disposal container. 
     <br/>
                              <content styleCode="bold">Do not</content>reuse the autoinjector or clear cap.
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" styleCode="Lrule Rrule">If you do not have an FDA-cleared sharps container, you may use a household container that is:
    
     <list listType="unordered" styleCode="Disc">
                                 <item>made of a heavy-duty plastic,</item>
                                 <item>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,</item>
                                 <item>upright and stable during use,</item>
                                 <item>leak-resistant, and</item>
                                 <item>properly labelled to warn of hazardous waste inside the container.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" styleCode="Lrule Rrule">When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used autoinjectors.</td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" styleCode="Lrule Rrule">For more information about safe sharps disposal, and specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">Do not</content>throw away your used sharps disposal container in your household trash unless your community guidelines permit this.
    
     <content styleCode="bold">Do not</content>recycle your used sharps disposal container.
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" styleCode="Lrule Rrule">For more information, go to https://www.TRYNGOLZA.com or call 1-833-644-6647. If you still have questions, contact your healthcare provider.</td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" styleCode="Lrule Rrule">Distributed by: Ionis Pharmaceuticals, Inc., Carlsbad, CA 92010</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
               </text>
               <effectiveTime value="20241223"/>
               <component>
                  <observationMedia ID="MM6">
                     <text>Figure 4</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="tryngolza-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM7">
                     <text>Figure 5</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="tryngolza-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM8">
                     <text>Figure 6</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="tryngolza-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM9">
                     <text>Figure 7</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="tryngolza-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM10">
                     <text>Figure 8</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="tryngolza-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM11">
                     <text>Figure 9</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="tryngolza-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM12">
                     <text>Figure 10</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="tryngolza-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM13">
                     <text>Figure 11</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="tryngolza-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM14">
                     <text>Figure 12</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="tryngolza-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM15">
                     <text>Figure 13</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="tryngolza-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM16">
                     <text>Figure 14</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="tryngolza-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM17">
                     <text>Figure 15</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="tryngolza-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Le86faab5-9eb3-432e-8065-e4ca7fc48470">
                     <text>Figure 16</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="tryngolza-16.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM19">
                     <text>Figure 17</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="tryngolza-17.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="34f9bf77-6dbf-5782-e063-6294a90a6c54"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 80 mg/0.8 mL Autoinjector Carton</title>
               <text>
                  <paragraph>Tryngolzaâ¢ 
  <br/>  (olezarsen) injection 
  <br/>  80 mg/0.8 mL
 </paragraph>
                  <paragraph>For subcutaneous use 
  <br/>  One single-dose autoinjector
 </paragraph>
                  <paragraph>Each TRYNGOLZA autoinjector contains 80 mg 
  <br/>  olezarsen (equivalent to 84 mg olezarsen sodium) 
  <br/>  in 0.8 mL of solution, single-dose, and is for the 
  <br/>  treatment of adult patients withÂ familial 
  <br/>  chylomicronemia syndrome (FCS).
 </paragraph>
                  <paragraph>IONIS
 
  <sup>Â®</sup>
                  </paragraph>
                  <paragraph>NDC 71860-101-01</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>Discard after ____ / ____ / ____</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="La8013d82-c991-4c40-945e-0b140bb53217"/>
                  </paragraph>
               </text>
               <effectiveTime value="20241223"/>
               <component>
                  <observationMedia ID="La8013d82-c991-4c40-945e-0b140bb53217">
                     <text>Figure 18</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="tryngolza-18.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>